Free Trial
NASDAQ:RVPH

Reviva Pharmaceuticals Q2 2024 Earnings Report

Reviva Pharmaceuticals logo
$0.49 +0.13 (+35.12%)
Closing price 10/2/2025 04:00 PM Eastern
Extended Trading
$0.57 +0.08 (+16.03%)
As of 06:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.28
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Reviva Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Reviva Pharmaceuticals Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
2:00AM ET

Upcoming Earnings

Reviva Pharmaceuticals' Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled on Friday, November 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Reviva Pharmaceuticals Earnings Headlines

Chardan Capital Initiates Coverage on Reviva Pharmaceuticals (NASDAQ:RVPH)
Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.tc pixel
Reviva Pharmaceuticals Amends Bylaws to Ease Quorum
See More Reviva Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals (NASDAQ:RVPH), Inc. (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings. Reviva maintains a lean operating model, leveraging partnerships with contract development and manufacturing organizations (CDMOs) to accelerate product development and optimize market entry.

Reviva’s current offerings span oral, injectable and topical dosage forms across therapeutic areas including metabolic disorders, dermatology and ophthalmology. In addition to its marketed portfolio, the company is advancing reformulation projects designed to improve delivery profiles, simplify dosing regimens and extend product lifecycles for previously approved drugs.

Led by Chief Executive Officer Mark C. Capparelli, Reviva’s management team combines expertise in pharmaceutical development, regulatory strategy and commercialization. The company serves markets throughout North America and works with specialty distributors in select regions to ensure broad patient access to its branded and licensed products.

View Reviva Pharmaceuticals Profile

More Earnings Resources from MarketBeat